


Formula I

wherein

R^1 is selected from the group consisting of N, CR^2, carbocyclyl and heterocyclyl, where any carbocyclyl or heterocyclyl in R^1 is optionally substituted with one or more R^3;

each R^3 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-4C)alkyl, (1-4C)haloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, aryl, aryl(1-3C)alkyl, heteroaryl, heteroaryl(1-3C)alkyl, carbocyclyl, carbocyclyl(1-3C)alkyl, heterocyclyl, heterocyclyl(1-3C)alkyl, $-OR^{3a}$, $-NR^{3a}R^{3b}$, $-C(O)-R^{3a}$, $-C(O)-OR^{3a}$, $-O-C(O)-R^{3a}$, $-C(O)-NR^{3a}R^{3b}$, $-N(R^{3a})C(O)-R^{3b}$ and $-S(O)_{0-2}R^{3a}$, where any (1-4C)alkyl, (1-4C)haloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, aryl, aryl(1-3C)alkyl, heteroaryl, heteroaryl(1-3C)alkyl, carbocyclyl, carbocyclyl(1-3C)alkyl, heterocyclyl or heterocyclyl(1-3C)alkyl in R^3 is optionally substituted with one or more R^{3c};

R^{3a} and R^{3b} are each independently selected from the group consisting of hydrogen, (1-3C)alkyl and (1-3C)haloalkyl;

each R^{3c} is independently selected from the group consisting of hydroxy, halogen, cyano, amino, (1-3C)alkyl, (1-3C)alkoxy and (1-3C)haloalkyl;

R^2 is selected from the group consisting of hydrogen, hydroxy, cyano, halogen, (1-4C)alkyl, (1-4C)haloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, aryl, aryl(1-3C)alkyl, heteroaryl, heteroaryl(1-3C)alkyl, carbocyclyl, carbocyclyl(1-3C)alkyl, heterocyclyl, heterocyclyl(1-3C)alkyl, $-OR^{2a}$, $-NR^{2a}R^{2b}$, $-C(O)-R^{2a}$, $-C(O)-OR^{2a}$, $-O-C(O)-R^{2a}$, $-C(O)-NR^{2a}R^{2b}$, $-N(R^{2a})C(O)-R^{2b}$ and $-S(O)_{0-2}R^{9a}$, where any (1-4C)alkyl, (1-4C)haloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, aryl, aryl(1-3C)alkyl,

heteroaryl, heteroaryl(1-3C)alkyl, carbocyclyl, carbocyclyl(1-3C)alkyl, heterocyclyl or heterocyclyl(1-3C)alkyl in R^2 is optionally substituted with one or more R^{2c};

R^{2a} and R^{2b} are each independently selected from the group consisting of hydrogen, (1-3C)alkyl and (1-3C)haloalkyl;

each R^{2c} is independently selected from the group consisting of hydroxy, halogen, cyano, amino, (1-3C)alkyl, (1-3C)alkoxy and (1-3C)haloalkyl;

each L^1 is a group:

$$-(W)_n-(X)_m-(Y)_o-(Z)_p-$$

in which

n and o are each independently 0, 1 or 2, and m and p are each independently 0 or 1, with the provisos that when m and p are both 1, o is not 0;

each W is selected from the group consisting of (1-3C)alkylene, (2-3C)alkenylene, (2-3C)alkynylene, arylene, heteroarylene, carbocyclylene and heterocyclylene, where any (1-3C)alkylene, (2-3C)alkenylene, (2-3C)alkynylene, arylene, heteroarylene, carbocyclylene or heterocyclylene in W is optionally substituted with one or more W^a, where each W^a is independently selected from the group consisting of hydroxy, cyano, halogen, amino, (1-2)alkoxy and (1-2C)haloalkyl;


X is selected from the group consisting of -O-, -C(O)-, -C(O)-O-, -O-C(O)-, $-S(O)_{0-2}-$, $-C(O)-N(R^x)-$, $-N(R^x)-C(O)-$, $-NR^x-$, $-N(R^x)-C(O)-NR^x-$, $-SO_2N(R^x)-$, and $-N(R^x)SO_2$, where each R^x is independently selected from the group consisting of hydrogen, hydroxy, cyano, (1-4C)alkyl, (2-4C)alkenyl and (2-4C)alkynyl;

each Y is selected from the group consisting of (1-3C)alkylene, (2-3C)alkenylene, (2-3C)alkynylene, arylene, heteroarylene, carbocyclylene and heterocyclylene, where any (1-3C)alkylene, (2-3C)alkenylene, (2-3C)alkynylene, arylene, heteroarylene, carbocyclylene or heterocyclylene in Y is optionally substituted with one or more Y^a, where each Y^a is independently selected from the group consisting of hydroxy, cyano, halogen, amino, (1-2)alkoxy and (1-2C)haloalkyl;

Z is selected from the group consisting of -O-, -C(O)-, -C(O)-O-, -O-C(O)-, $-S(O)_{0-2}-$, $-C(O)-N(R^z)-$, $-N(R^z)-C(O)-$, $-NR^z-$, $-N(R^z)-C(O)-NR^z-$, $-SO_2N(R^z)-$, and $-N(R^z)SO_2$, where each R^z is independently selected from the group consisting of hydrogen, hydroxy, cyano, (1-4C)alkyl, (2-4C)alkenyl and (2-4C)alkynyl;

X^a is a ring heteroatom located within ring A and is N;

each ring A is group:



wherein a is 0 or 1 and

R^4 is selected from the group consisting of hydroxy, cyano, halogen, (1-6C)alkyl, (1-6C)haloalkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, aryl(1-3C)alkyl, heteroaryl, heteroaryl(1-3C)alkyl, carbocyclyl, carbocyclyl(1-3C)alkyl, heterocyclyl, heterocyclyl(1-3C)alkyl, $-R^{4a}-OR^{4b}$, $-R^{4a}-NR^{4b}R^{4c}$, $-R^{4a}-C(O)-R^{4b}$, $-R^{4a}-C(O)-OR^{4b}$, $-R^{4a}-O-C(O)-R^{4b}$, $-R^{4a}-C(O)-NR^{4b}R^{4c}$, $-R^{4a}-N(R^{4b})C(O)-R^{4c}$ and $-R^{4a}-S(O)_{0-2}R^{4b}$, where any (1-6C)alkyl, (1-6C)haloalkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, aryl(1-3C)alkyl, heteroaryl, heteroaryl(1-3C)alkyl, carbocyclyl, carbocyclyl(1-3C)alkyl, heterocyclyl or heterocyclyl(1-3C)alkyl in R^4 is optionally substituted with one or more R^{4d};

R^{4a} is absent or is (1-3C)alkylene that is optionally substituted with one or substituents selected from group consisting of hydroxy, halo and amino;

R^{4b} and R^{4c} are each independently selected from the group consisting of hydrogen, (1-3C)alkyl and (1-3C)haloalkyl;

each R^{4d} is independently selected from the group consisting of hydroxy, halogen, cyano, amino, (1-3C)alkyl, (1-3C)alkoxy and (1-3C)haloalkyl;

X^b is a ring heteroatom located within ring B and is selected from N and O

each ring B is a monocyclic heteroaryl, bicyclic heteroaryl, monocyclic heterocycle or bicyclic heterocycle, any one of which is optionally substituted with one or more R^5, where each R^5 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-6C)alkyl, (1-6C)haloalkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, aryl(1-3C)alkyl, heteroaryl, heteroaryl(1-3C)alkyl, carbocyclyl, carbocyclyl(1-3C)alkyl, heterocyclyl, heterocyclyl(1-3C)alkyl, $-R^{5a}-OR^{5b}$, $-R^{5a}-NR^{5b}R^{5c}$, $-R^{5a}-C(O)-R^{5b}$, $-R^{5a}-C(O)-OR^{5b}$, $-R^{5a}-O-C(O)-R^{5b}$, $-R^{5a}-C(O)-NR^{5b}R^{5c}$, $-R^{5a}-N(R^{5b})C(O)-R^{5c}$ and $-R^{5a}-S(O)_{0-2}R^{5b}$, where any (1-6C)alkyl, (1-6C)haloalkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, aryl(1-3C)alkyl, heteroaryl, heteroaryl(1-3C)alkyl, carbocyclyl, carbocyclyl(1-3C)alkyl, heterocyclyl or heterocyclyl(1-3C)alkyl in R^5 is optionally substituted with one or more R^{5d};

R^{5a} is absent or is (1-3C)alkylene that is optionally substituted with one or substituents selected from group consisting of hydroxy, halo and amino;


R^{5b} and R^{5c} are each independently selected from the group consisting of hydrogen, (1-5C)alkyl (e.g. (1-3C)alkyl) and (1-3C)haloalkyl;

each R^{5d} is independently selected from the group consisting of hydroxy, halogen, cyano, amino, (1-3C)alkyl, (1-3C)alkoxy and (1-3C)haloalkyl; and

each L^2 is selected from the group consisting of absent (in which case ring A is bonded directly to ring B), (1-2C)alkylene, ethenylene and ethynylene, where any (1-2C)alkylene, ethenylene and ethynylene in L^2 is optionally substituted with one or more substituents selected form the group consisting of hydroxy, halogen, cyano, amino, (1-3C)alkyl, (1-3C)alkoxy and (1-3C)haloalkyl;

and wherein the compound of Formula I, or the pharmaceutically acceptable salt, hydrate or solvate thereof, is for use in combination with a source of M, wherein M is selected from the group consisting of Zn^{2+}, Mn^{2+}, Cu^{2+}, Fe^{2+} and Co^{2+}.

[0007b] In another aspect of the present disclosure, there is provided a compound having a structure according to Formula II shown below, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use as a medicament:




Formula II

wherein

M, R^1, L^1, A, X^a, L^2, B, X^b and any associated subgroups are as disclosed herein.

[0007c] In yet another aspect of the present disclosure, there is provided a compound having a structure according to Formula III shown below, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use as a medicament:



Formula III

wherein

M, Q, R^1, L^1, A, X^a, L^2, B, X^b and any associated subgroups are as disclosed herein.


[0007d] In a further aspect of the present disclosure, there is provided the compound, pharmaceutically acceptable salt, hydrate or solvate for use as disclosed herein, wherein the medicament is for the treatment of cancer.

[0007e] In another aspect of the present disclosure, there is provided a use of the compound, pharmaceutically acceptable salt, hydrate or solvate as disclosed herein, in the manufacture of a medicament for treatment of a proliferative disorder (e.g. cancer).

[0008] Thus, according to a first example of the present disclosure there is provided a compound having a structure according to Formula I as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, with the proviso that the compound is not Compound Ia defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof.

CLAIMS

1. A compound having a structure according to Formula I shown below, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use as a medicament:



Formula I

wherein

R^1 is selected from the group consisting of N, CR^2, carbocyclyl and heterocyclyl, where any carbocyclyl or heterocyclyl in R^1 is optionally substituted with one or more R^3;

each R^3 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-4C)alkyl, (1-4C)haloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, aryl, aryl(1-3C)alkyl, heteroaryl, heteroaryl(1-3C)alkyl, carbocyclyl, carbocyclyl(1-3C)alkyl, heterocyclyl, heterocyclyl(1-3C)alkyl, $-OR^{3a}$, $-NR^{3a}R^{3b}$, $-C(O)-R^{3a}$, $-C(O)-OR^{3a}$, $-O-C(O)-R^{3a}$, $-C(O)-NR^{3a}R^{3b}$, $-N(R^{3a})C(O)-R^{3b}$ and $-S(O)_{0-2}R^{3a}$, where any (1-4C)alkyl, (1-4C)haloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, aryl, aryl(1-3C)alkyl, heteroaryl, heteroaryl(1-3C)alkyl, carbocyclyl, carbocyclyl(1-3C)alkyl, heterocyclyl or heterocyclyl(1-3C)alkyl in R^3 is optionally substituted with one or more R^{3c};

R^{3a} and R^{3b} are each independently selected from the group consisting of hydrogen, (1-3C)alkyl and (1-3C)haloalkyl;

each R^{3c} is independently selected from the group consisting of hydroxy, halogen, cyano, amino, (1-3C)alkyl, (1-3C)alkoxy and (1-3C)haloalkyl;

R^2 is selected from the group consisting of hydrogen, hydroxy, cyano, halogen, (1-4C)alkyl, (1-4C)haloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, aryl, aryl(1-3C)alkyl, heteroaryl, heteroaryl(1-3C)alkyl, carbocyclyl, carbocyclyl(1-3C)alkyl, heterocyclyl, heterocyclyl(1-3C)alkyl, $-OR^{2a}$, $-NR^{2a}R^{2b}$, $-C(O)-R^{2a}$, $-C(O)-OR^{2a}$, $-O-C(O)-R^{2a}$, $-C(O)-NR^{2a}R^{2b}$, $-N(R^{2a})C(O)-R^{2b}$ and $-S(O)_{0-2}R^{9a}$, where any (1-4C)alkyl, (1-4C)haloalkyl, (2-4C)alkenyl, (2-4C)alkynyl, aryl, aryl(1-3C)alkyl, heteroaryl, heteroaryl(1-3C)alkyl, carbocyclyl, carbocyclyl(1-3C)alkyl, heterocyclyl or heterocyclyl(1-3C)alkyl in R^2 is optionally substituted with one or more R^{2c};

R^{2a} and R^{2b} are each independently selected from the group consisting of hydrogen, (1-3C)alkyl and (1-3C)haloalkyl;

each R^{2c} is independently selected from the group consisting of hydroxy, halogen, cyano, amino, (1-3C)alkyl, (1-3C)alkoxy and (1-3C)haloalkyl;

each L^1 is a group:

$$-(W)_n-(X)_m-(Y)_o-(Z)_p-$$

in which

n and o are each independently 0, 1 or 2, and m and p are each independently 0 or 1, with the provisos that when m and p are both 1, o is not 0;

each W is selected from the group consisting of (1-3C)alkylene, (2-3C)alkenylene, (2-3C)alkynylene, arylene, heteroarylene, carbocyclylene and heterocyclylene, where any (1-3C)alkylene, (2-3C)alkenylene, (2-3C)alkynylene, arylene, heteroarylene, carbocyclylene or heterocyclylene in W is optionally substituted with one or more W^a, where each W^a is independently selected from the group consisting of hydroxy, cyano, halogen, amino, (1-2)alkoxy and (1-2C)haloalkyl;

X is selected from the group consisting of -O-, -C(O)-, -C(O)-O-, -O-C(O)-, $-S(O)_{0-2}-$, $-C(O)-N(R^x)-$, $-N(R^x)-C(O)-$, $-NR^x-$, $-N(R^x)-C(O)-NR^x-$, $-SO_2N(R^x)-$, and $-N(R^x)SO_2$, where each R^x is


independently selected from the group consisting of hydrogen, hydroxy, cyano, (1-4C)alkyl, (2-4C)alkenyl and (2-4C)alkynyl;

each Y is selected from the group consisting of (1-3C)alkylene, (2-3C)alkenylene, (2-3C)alkynylene, arylene, heteroarylene, carbocyclylene and heterocyclylene, where any (1-3C)alkylene, (2-3C)alkenylene, (2-3C)alkynylene, arylene, heteroarylene, carbocyclylene or heterocyclylene in Y is optionally substituted with one or more Y^a, where each Y^a is independently selected from the group consisting of hydroxy, cyano, halogen, amino, (1-2)alkoxy and (1-2C)haloalkyl;

Z is selected from the group consisting of -O-, -C(O)-, -C(O)-O-, -O-C(O)-, -$S(O)_{0-2}$-, -C(O)-$N(R^z)$-, -$N(R^z)$-C(O)-, -NR^z-, -$N(R^z)$-C(O)-NR^z-, -$SO_2N(R^z)$-, and -$N(R^z)SO_2$, where each R^z is independently selected from the group consisting of hydrogen, hydroxy, cyano, (1-4C)alkyl, (2-4C)alkenyl and (2-4C)alkynyl;

X^a is a ring heteroatom located within ring A and is N;

each ring A is group:



wherein a is 0 or 1 and

R^4 is selected from the group consisting of hydroxy, cyano, halogen, (1-6C)alkyl, (1-6C)haloalkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, aryl(1-3C)alkyl, heteroaryl, heteroaryl(1-3C)alkyl, carbocyclyl, carbocyclyl(1-3C)alkyl, heterocyclyl, heterocyclyl(1-3C)alkyl, -R^{4a}-OR^{4b}, -R^{4a}-$NR^{4b}R^{4c}$, -R^{4a}-C(O)-R^{4b}, -R^{4a}-C(O)-OR^{4b}, -R^{4a}-O-C(O)-R^{4b}, -R^{4a}-C(O)-$NR^{4b}R^{4c}$, -R^{4a}-$N(R^{4b})$C(O)-R^{4c} and -R^{4a}-$S(O)_{0-2}R^{4b}$, where any (1-6C)alkyl, (1-6C)haloalkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, aryl(1-3C)alkyl, heteroaryl, heteroaryl(1-3C)alkyl, carbocyclyl, carbocyclyl(1-3C)alkyl, heterocyclyl or heterocyclyl(1-3C)alkyl in R^4 is optionally substituted with one or more R^{4d};

R^{4a} is absent or is (1-3C)alkylene that is optionally substituted with one or substituents selected from group consisting of hydroxy, halo and amino;

R^{4b} and R^{4c} are each independently selected from the group consisting of hydrogen, (1-3C)alkyl and (1-3C)haloalkyl;

each R^{4d} is independently selected from the group consisting of hydroxy, halogen, cyano, amino, (1-3C)alkyl, (1-3C)alkoxy and (1-3C)haloalkyl;

X^b is a ring heteroatom located within ring B and is selected from N and O

each ring B is a monocyclic heteroaryl, bicyclic heteroaryl, monocyclic heterocycle or bicyclic heterocycle, any one of which is optionally substituted with one or more R^5, where each R^5 is independently selected from the group consisting of hydroxy, cyano, halogen, (1-6C)alkyl, (1-6C)haloalkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, aryl(1-3C)alkyl, heteroaryl, heteroaryl(1-3C)alkyl, carbocyclyl, carbocyclyl(1-3C)alkyl, heterocyclyl, heterocyclyl(1-3C)alkyl, $-R^{5a}-OR^{5b}$, $-R^{5a}-NR^{5b}R^{5c}$, $-R^{5a}-C(O)-R^{5b}$, $-R^{5a}-C(O)-OR^{5b}$, $-R^{5a}-O-C(O)-R^{5b}$, $-R^{5a}-C(O)-NR^{5b}R^{5c}$, $-R^{5a}-N(R^{5b})C(O)-R^{5c}$ and $-R^{5a}-S(O)_{0-2}R^{5b}$, where any (1-6C)alkyl, (1-6C)haloalkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, aryl(1-3C)alkyl, heteroaryl, heteroaryl(1-3C)alkyl, carbocyclyl, carbocyclyl(1-3C)alkyl, heterocyclyl or heterocyclyl(1-3C)alkyl in R^5 is optionally substituted with one or more R^{5d};

R^{5a} is absent or is (1-3C)alkylene that is optionally substituted with one or substituents selected from group consisting of hydroxy, halo and amino;

R^{5b} and R^{5c} are each independently selected from the group consisting of hydrogen, (1-5C)alkyl (e.g. (1-3C)alkyl) and (1-3C)haloalkyl;


each R^{5d} is independently selected from the group consisting of hydroxy, halogen, cyano, amino, (1-3C)alkyl, (1-3C)alkoxy and (1-3C)haloalkyl; and

each L^2 is selected from the group consisting of absent (in which case ring A is bonded directly to ring B), (1-2C)alkylene, ethenylene and ethynylene, where any (1-2C)alkylene, ethenylene and ethynylene in L^2 is optionally substituted with one or more substituents selected form the group consisting of hydroxy, halogen, cyano, amino, (1-3C)alkyl, (1-3C)alkoxy and (1-3C)haloalkyl;

and wherein the compound of Formula I, or the pharmaceutically acceptable salt, hydrate or solvate thereof, is for use in combination with a source of M, wherein M is selected from the group consisting of Zn^{2+}, Mn^{2+}, Cu^{2+}, Fe^{2+} and Co^{2+}.

2. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to claim 1, wherein each ring B is:
i) a 5-6 membered monocyclic heterocycle containing 1, 2 or 3 ring heteroatoms in total that are independently selected from N, O and S;
ii) a 5-6 membered monocyclic heteroaryl containing 1, 2 or 3 ring heteroatoms in total that are independently selected from N, O and S;
iii) a 9-10 membered bicyclic heterocycle containing 1, 2 or 3 ring heteroatoms in total that are independently selected from N, O and S; or
iv) a 9-10 membered bicyclic heteroaryl containing 1, 2 or 3 ring heteroatoms in total that are independently selected from N, O and S,
wherein any ring in B is optionally substituted with one or more R^5, and
X^b is located immediately adjacent the carbon atom bonded to L^2.

3. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to any preceding claim, wherein each ring B is any of the following:




wherein:
b^1 is 0, 1 or 2, and
b^2 is 0, 1, 2 or 3.

4. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to any preceding claim, wherein
each W is selected from the group consisting of (1-3C)alkylene or phenylene, where any (1-3C)alkylene or phenylene in W is optionally substituted with one or more W^a;
X is selected from the group consisting of -C(O)-N(R^x)-, -N(R^x)-C(O)- and -NR^x-;
each Y is selected from the group consisting of (1-3C)alkylene or phenylene, where any (1-3C)alkylene or phenylene in Y is optionally substituted with one or more Y^a; and

Z is selected from the group consisting of -C(O)-N(R^z)-, -N(R^z)-C(O)- and -NR^z-.

5. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to any preceding claim, wherein:
n is 0 or 1 and W is selected from the group consisting of (1-3C)alkylene or phenylene, where any (1-3C)alkylene or phenylene in W is optionally substituted with one or more W^a, where each W^a is independently selected from the group consisting of hydroxy, halogen, (1-2)alkoxy and (1-2C)haloalkyl;
m is 0;
o is 0 or 1 and Y is selected from the group consisting of (1-3C)alkylene or phenylene, where any (1-3C)alkylene or phenylene in Y is optionally substituted with one or more Y^a, where each Y^a is independently selected from the group consisting of hydroxy, halogen, (1-2)alkoxy and (1-2C)haloalkyl; and
p is 1 and Z is -NR^z-, where R^z is hydrogen.

6. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to any preceding claim, wherein L^1 has a structure according to any one of the following:




7. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to any preceding claim, wherein L^2 is selected from the group consisting of absent and (1-2C)alkylene, where any (1-2C)alkylene in L^2 is optionally substituted with one or more substituents selected form the group consisting of hydroxy, halogen and (1-2C)haloalkyl.

8. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to any preceding claim, wherein
R^1 is selected from the group consisting of N, CR^2 and cyclohexyl, where any cyclohexyl in R^1 is optionally substituted with one or more R^3;


each R^3 is independently selected from the group consisting of hydroxy, halogen, (1-4C)alkyl, (1-4C)haloalkyl and -OR^{3a}, where any (1-4C)alkyl or (1-4C)haloalkyl in R^3 is optionally substituted with one or more R^{3c};
R^2 is selected from the group consisting of hydrogen, and (1-3C)alkyl, where any (1-4C)alkyl in R^2 is optionally substituted with one or more R^{2c}.

9. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to any preceding claim, wherein R^1 has a structure according to any one of the following:



10. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to any preceding claim, wherein R^{5b} and R^{5c} are each independently selected from the group consisting of hydrogen, (1-3C)alkyl and (1-3C)haloalkyl.

11. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to any preceding claim, wherein the compound has a structure according to Formula I-X:



Formula I-X

wherein

q is 2;

each R^5 is as defined in any preceding claim, or two R^5 groups located on adjacent carbon atoms are linked, such that when taken in combination with the atoms to which they are attached, they form a fused benzene ring; and

R^4, a and b^1 are as defined in any preceding claim.

12. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to any preceding claim, wherein M is selected from the group consisting of Zn^{2+}, Cu^{2+}, Mn^{2+} and Fe^{2+}.


13. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to any preceding claim, wherein M is selected from the group consisting of Zn^{2+} and Mn^{2+}.


14. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to any preceding claim, wherein the compound of Formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, is in further combination with a source of Q, wherein Q is an anion selected from the group consisting of spherical monoanionic anions, trigonal planar anions, dianionic tetrahedral anions, trianionic tetrahedral anions, dianionic octahedral anions and trianionic octahedral anions.


15. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to claim 14, wherein Q is an anion selected from the group consisting of dianionic tetrahedral oxoanions and trianionic tetrahedral oxoanions.


16. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to claim 14 or 15, wherein Q is sulfate (SO_4^{2-}), phosphate (PO_4^{3-}) or organophosphate (such as monophenylphosphate).


17. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to any preceding claim, wherein the compound of Formula I has a structure according to any one of the following:



















or a pharmaceutically-acceptable salt, hydrate and/or solvate thereof.

18. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to any preceding claim, wherein the compound of Formula I has the structure:




or a pharmaceutically-acceptable salt, hydrate and/or solvate thereof.

19. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to any preceding claim, wherein the compound of Formula I has the structure:



or a pharmaceutically-acceptable salt, hydrate or solvate thereof;
and wherein M is selected from the group consisting of Zn^{2+} and Mn^{2+}.

20. A compound having a structure according to Formula II shown below, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use as a medicament:




Formula II

wherein
M, R^1, L^1, A, X^a, L^2, B, X^b and any associated subgroups are as defined in any preceding claim.

21. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to claim 20, wherein the compound of Formula II, or a pharmaceutically


acceptable salt, hydrate or solvate thereof, is in further combination with a source of Q as defined in any one of claims 14, 15 and 16.

22. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to claim 20 or 21, wherein the compound of Formula II has a structure according to any one of the following:



or a pharmaceutically-acceptable salt, hydrate and/or solvate thereof.

23. A compound having a structure according to Formula III shown below, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use as a medicament:





Formula III


wherein


M, Q, R^1, L^1, A, X^a, L^2, B, X^b and any associated subgroups are as defined in any one of claims 1-19.


24. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to claim 23, wherein the compound of Formula III has a structure according to any one of the following:











or a pharmaceutically-acceptable salt, hydrate and/or solvate thereof.

25. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to any preceding claim, wherein the medicament is for the treatment of cancer.

26. The compound, pharmaceutically acceptable salt, hydrate or solvate for use according to claim 25, wherein the cancer is colon cancer, pancreas cancer, lung cancer or brain cancer.

27. Use of the compound, pharmaceutically acceptable salt, hydrate or solvate according to claims 1-24, in the manufacture of a medicament for treatment of a proliferative disorder (e.g. cancer).